{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:44:01Z","timestamp":1793043841663,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clml.2020.01.008","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:55:57Z","timestamp":1582718157000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6175","authenticated-orcid":false,"given":"Bridget K.","family":"Marcellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.01.008_bib1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2007.1.346","article-title":"Biology and treatment of primary myelofibrosis","author":"Hoffman","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2020.01.008_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/2040620712437754","article-title":"Myelofibrosis 2012: it's complicated","volume":"3","author":"Hubbeling","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2020.01.008_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cam4.136","article-title":"Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review","volume":"2","author":"Mitra","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2020.01.008_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","article-title":"Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival","volume":"84","author":"Patnaik","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib5","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A\u00a0clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.01.008_bib6","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/JCO.2016.34.15_suppl.7068","article-title":"Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count\u00a0<50\u00a0\u00d7 109\/L: a single-center experience in 1100 myelofibrosis patients","volume":"34","author":"Alhuraiji","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.008_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hernandez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1179\/2295333714Y.0000000097","article-title":"Myelofibrosis patients in Belgium: disease characteristics","volume":"70","author":"Devos","year":"2015","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.clml.2020.01.008_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2020.01.008_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cncr.21644","article-title":"Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.01.008_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.008_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.01.008_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-018-0453-y","article-title":"Post-ET and post-PV myelofibrosis: updates on a distinct prognosis from primary myelofibrosis","volume":"13","author":"Passamonti","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2020.01.008_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2020.01.008_bib16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.008_bib17","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib18","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib19","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib21","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2013-07-515676","article-title":"JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.01.008_bib23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time","volume":"135","author":"Lasho","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.008_bib26","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.01.008_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.008_bib28","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.008_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.01.008_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","article-title":"Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts","volume":"6","author":"Talpaz","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2020.01.008_bib32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.008_bib33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2020.01.008_bib35","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.008_bib37","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2018-99-115407","article-title":"Janus kinase (Jak) 1 inhibition affects both megakaryopoiesis and thrombopoiesis","volume":"132","author":"Jarocha","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","article-title":"A\u00a0phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.008_bib39","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib40","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.01.008_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2020.01.008_bib42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2019-129293","article-title":"Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib43","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V128.22.3131.3131","volume":"128","author":"Vannucchi","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2020.01.008_bib44","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2019-127609","article-title":"The Oral JAK2\/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden","volume":"134","author":"Verstovsek","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.008_bib45","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.clml.2019.07.374","article-title":"Fedratinib induces spleen responses and reduces symptom burden as first-line or salvage therapy in patients with myeloproliferative neoplasm-associated intermediate- or high-risk myelofibrosis (MF) and low platelet counts","volume":"19","author":"Harrison","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.008_bib46","first-page":"11","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J\u00a0Exp Pharmacol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:24Z","timestamp":1761870864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2152265020300458"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}